Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will …

hodgkin's disease
richter's transformation
diffuse large b-cell lymphoma
richter's syndrome
lymphoma
  • 7 views
  • 15 May, 2022
  • 8 locations
Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma

This pilot phase I trial studies the side effects of atezolizumab, gemcitabine, oxaliplatin, and rituximab and to see how well they work in treating patients with transformed diffuse large B-cell lymphoma that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help …

marginal zone lymphoma
gilbert's syndrome
measurable disease
aptt
neutrophil count
  • 39 views
  • 17 Jun, 2022
  • 1 location
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

This phase I trial studies the best dose and how well copanlisib when given together with nivolumab works in treating patients with Richter's transformation or transformed indolent non-Hodgkin lymphoma. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal …

marginal zone lymphoma
neutrophil count
hodgkin's disease
indolent lymphoma
tumor cells
  • 17 views
  • 09 Apr, 2022
  • 2 locations
A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

marginal zone lymphoma
gilbert's syndrome
measurable disease
b-cell small lymphocytic lymphoma
neutrophil count
  • 420 views
  • 15 Mar, 2022
  • 10 locations
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia

measurable disease
anti-cd20 monoclonal antibody
monoclonal protein
b-cell lymphoma
lymphoma
  • 0 views
  • 29 May, 2022
  • 5 locations
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

chemotherapy regimen
ejection fraction
white blood cells
gilbert's syndrome
neutrophil count
  • 2 views
  • 17 Jun, 2022
  • 2 locations
ALX148 Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, may induce changes in body's immune system and may interfere with the ability of cancer …

  • 0 views
  • 02 Dec, 2021
  • 1 location
A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

measurable disease
carcinoma
growth factors
fallopian tube
systemic therapy
  • 0 views
  • 07 Jun, 2022
  • 6 locations
Genomic and Proteomic Study of Richter Syndrome (CGPSR) (CGPSR)

Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive Diffuse Large B

Accepts healthy volunteers
  • 0 views
  • 12 Feb, 2022
  • 1 location